|

Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

RECRUITINGPhase 2Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Actively Recruiting
PhasePhase 2
SponsorCentre hospitalier de l'Université de Montréal (CHUM)
Started2019-07-01
Est. completion2025-05-30
Eligibility
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04100174

Summary

To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL

Eligibility

Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
* ECOG 0-1
* Charlson Comorbidity Index ≤ 4
* Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.

Exclusion - none

Conditions2

CancerProstate Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.